Cortactin and phosphorylated cortactin tyr466 expression in temporal bone carcinoma
| Autor: | Laura Girasoli, Gino Marioni, Alessandro Martini, Stella Blandamura, Elisabetta Zanoletti, Elisa Valentini, Luciano Giacomelli, Antonio Mazzoni, Andrea Gianatti, Martina Guariento |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty biology business.industry Cell migration macromolecular substances 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Otorhinolaryngology Downregulation and upregulation 030220 oncology & carcinogenesis Cancer research biology.protein Medicine Phosphorylation Immunohistochemistry Tyrosine business Cytoskeleton Actin Cortactin |
| Popis: | Purpose Cortactin is a multidomain protein engaged in several cellular mechanisms involving actin assembly and cytoskeletal arrangement. Cortactin overexpression in several malignancies has been associated with increased cell migration, invasion, and metastatic potential. Cortactin needs to be activated by tyrosine or serine/threonine phosphorylation. The role of cortactin and phosphorylated cortactin (residue tyr 466 ) was investigated in temporal bone squamous cell carcinoma (TBSCC). Materials and methods Immunohistochemical expression of cortactin and phosphorylated cortactin (residue tyr 466 ) was assessed in 27 consecutively-operated TBSCCs. Results Several clinicopathological variables correlated with recurrence (pT stage, dura mater involvement), and disease-free survival (DFS) (cT stage, pT stage, pN status, dura mater involvement). Twenty-three of 24 immunohistochemically evaluable TBSCCs were cortactin-positive. Median cortactin expression was 75.0%. Cortactin reaction in the cytoplasm was more intense in carcinoma cells than in normal adjacent tissue. Recurrence and DFS rates did not correlate with cortactin and phosphorylated cortactin (residue tyr 466 ) expression in TBSCC specimens. Conclusions Cortactin upregulation in TBSCC supports the conviction that inhibiting cortactin functions could have selective effects on this malignancy. Multi-institutional studies should further investigate the role of cortactin and phosphorylated cortactin in TBSCC, and their potential clinical application in integrated treatment modalities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|